Notably, high expression of SLFN11 in the SCLC-A subtype is associated with sensitivity to PARP inhibitors, while the SCLC-P subtype remains sensitive to PARP inhibitors even in the absence of high SLFN11 expression or low ATM expression. Here, SLFN11 is linked to small cell lung carcinoma.